KR950700063A - Brofaromine as an agent for treating post-traumatic stress - Google Patents
Brofaromine as an agent for treating post-traumatic stressInfo
- Publication number
- KR950700063A KR950700063A KR1019940702903A KR19940702903A KR950700063A KR 950700063 A KR950700063 A KR 950700063A KR 1019940702903 A KR1019940702903 A KR 1019940702903A KR 19940702903 A KR19940702903 A KR 19940702903A KR 950700063 A KR950700063 A KR 950700063A
- Authority
- KR
- South Korea
- Prior art keywords
- broparomin
- pharmaceutically acceptable
- effective amount
- acceptable salt
- warm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명에서는 브로파로민 또는 제약학상 허용되는 이의 염의 외상후 스트레스성 장해치료 유효량을 그러한 치료를 필요로 하는 온형 동물에게 투여함을 포함하여 온혈 동물의 외상후 스트레스성 장해를 치료하는 방법이 제공된다.The present invention provides a method for treating posttraumatic stress disorder in warm-blooded animals, including administering an effective amount of a posttraumatic stress disorder disorder of broparomin or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof. .
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83963992A | 1992-02-21 | 1992-02-21 | |
US07/839,639 | 1992-02-21 | ||
PCT/US1993/000728 WO1993016695A1 (en) | 1992-02-21 | 1993-01-27 | Brofaromine as an agent for treating post-traumatic stress |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950700063A true KR950700063A (en) | 1995-01-16 |
Family
ID=25280288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940702903A KR950700063A (en) | 1992-02-21 | 1993-01-27 | Brofaromine as an agent for treating post-traumatic stress |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0626849A1 (en) |
JP (1) | JPH07503972A (en) |
KR (1) | KR950700063A (en) |
AU (1) | AU676672B2 (en) |
CA (1) | CA2117430A1 (en) |
NZ (1) | NZ249041A (en) |
WO (1) | WO1993016695A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
EP1096927A4 (en) * | 1998-07-16 | 2002-09-04 | Massachusetts Inst Technology | Composition for treatment of stress |
IL149062A0 (en) * | 1999-10-12 | 2002-11-10 | Connex Ges Zur Optimierungvon | Improved method for detecting acid resistant microorganisms in the stool |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH592656A5 (en) * | 1973-03-02 | 1977-10-31 | Ciba Geigy Ag | |
AU3595093A (en) * | 1992-02-21 | 1993-09-13 | Ciba-Geigy Ag | Brofaromine as an agent for treating social phobia |
-
1993
- 1993-01-27 AU AU34844/93A patent/AU676672B2/en not_active Ceased
- 1993-01-27 CA CA002117430A patent/CA2117430A1/en not_active Abandoned
- 1993-01-27 JP JP5514855A patent/JPH07503972A/en active Pending
- 1993-01-27 NZ NZ249041A patent/NZ249041A/en unknown
- 1993-01-27 WO PCT/US1993/000728 patent/WO1993016695A1/en not_active Application Discontinuation
- 1993-01-27 EP EP93903683A patent/EP0626849A1/en not_active Withdrawn
- 1993-01-27 KR KR1019940702903A patent/KR950700063A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1993016695A1 (en) | 1993-09-02 |
AU3484493A (en) | 1993-09-13 |
CA2117430A1 (en) | 1993-09-02 |
EP0626849A1 (en) | 1994-12-07 |
NZ249041A (en) | 1997-07-27 |
AU676672B2 (en) | 1997-03-20 |
JPH07503972A (en) | 1995-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2203653C2 (en) | Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof | |
KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
KR950031069A (en) | How to suppress bone loss and lower serum cholesterol | |
RU94041223A (en) | Agent for motoneuron disease treatment | |
KR880011199A (en) | Novel peptide compounds, methods for their preparation and pharmaceutical compositions containing them | |
EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
UA41446C2 (en) | Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition | |
KR890001533A (en) | Pharmaceutical compositions containing levodopa methyl esters, their preparation and therapeutic applications | |
KR900701282A (en) | Treatment, prevention of ischemic diseases of the heart or brain | |
OA09023A (en) | Pharmaceutical composition, which can be administered orally, intended to reduce the effects of b-lactams. | |
DE59406938D1 (en) | PHARMACEUTICAL PREPARATIONS WITH AN ACTIVE SUBSTANCE CONTAINING MODIFIED AMIDINE GROUPS | |
KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
KR970025615A (en) | Cancer metastasis inhibitor | |
KR830002510A (en) | Composition consisting of biologically active compound and hydroxyalkyl starch | |
KR940702726A (en) | Use of substituted quinoline-3-carboxyamide compounds and methods of treating multiple sclerosis using the same | |
KR920019350A (en) | Pharmaceutical Compositions for Autoimmune Disease Therapy | |
RU97104483A (en) | SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT | |
ES2093246T3 (en) | THERAPEUTIC BENZAZEPINE COMPOUNDS. | |
KR920702225A (en) | Pharmaceutical composition | |
KR950700063A (en) | Brofaromine as an agent for treating post-traumatic stress | |
KR890004705A (en) | Antiviral agents | |
OA07029A (en) | Gallium chloride, a new anti-cancer drug. | |
KR890012942A (en) | 5-substituted ornithine derivatives | |
KR940013503A (en) | Pharmaceutical compositions for the prevention or treatment of atherosclerosis | |
KR960700711A (en) | Medicine for treating or preventing cerebrovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |